O-3 Clinical features and outcome measures during 1 year enzyme replacement therapy in late onset GSD II patients
نویسندگان
چکیده
O-3 Clinical features and outcome measures during 1 year enzyme replacement therapy in late onset GSD II patients C. Angelini, C. Semplicini, E. Pegoraro, M. Filosto, G. Marrosu R. Piras, T. Mongini, L. Vercelli, P. Tonin, S. Servidei, R. Di Giacopo, G. Crescimanno, S. Ravaglia, A. Toscano, O. Musumeci, G. Siciliano, G. Ricci, Di Iorio, F. Cipullo, M. Moggio, G. Comi, V. Lucchini, L. Morandi 1 University of Padova, Department of Neurosciences, Padova, Italy; 2 Hospital of Brescia, Italy; 3 University of Cagliari, Italy; 4 University of Torino, Centre for Neuromuscular Diseases, Department of Neurosciences, Torino, Italy; 5 University of Verona; 6 Catholic University of Rome, Italy; 7 University of Palermo, Italy; 8 University of Pavia, Italy; 9 Department of Neurosciences, Psichiatry and Anesthesiology, University of Messina, Italy; 10 University of Pisa, Italy; 11 Second University of Napoli; 12 Deparment of Neurological Sciences, University of Milan, Italy; 13 Besta Institute, Milan, Italy
منابع مشابه
O-5 Novel HLA II associations in myasthenia gravis
O-3 Clinical features and outcome measures during 1 year enzyme replacement therapy in late onset GSD II patients C. Angelini, C. Semplicini, E. Pegoraro, M. Filosto, G. Marrosu R. Piras, T. Mongini, L. Vercelli, P. Tonin, S. Servidei, R. Di Giacopo, G. Crescimanno, S. Ravaglia, A. Toscano, O. Musumeci, G. Siciliano, G. Ricci, Di Iorio, F. Cipullo, M. Moggio, G. Comi, V. Lucchini, L. Morandi 1 ...
متن کاملO-4 The Italian Network for Laminopathies
O-3 Clinical features and outcome measures during 1 year enzyme replacement therapy in late onset GSD II patients C. Angelini, C. Semplicini, E. Pegoraro, M. Filosto, G. Marrosu R. Piras, T. Mongini, L. Vercelli, P. Tonin, S. Servidei, R. Di Giacopo, G. Crescimanno, S. Ravaglia, A. Toscano, O. Musumeci, G. Siciliano, G. Ricci, Di Iorio, F. Cipullo, M. Moggio, G. Comi, V. Lucchini, L. Morandi 1 ...
متن کاملClinical, morphological and genetic features of a cohort of late onset GSD II patients: typical and atypical presentations
Results Out of 29 patients, 15 received enzyme replacement therapy (ERT). 57% initially had limb-girdle involvement, 29% an isolated hyperCKemia, and 14% respiratory insufficiency. Neurophysiological studies revealed a myopathic pattern in 48% of patients, neurogenic or mixed in 28%, whereas 24% of patients did not show any electrical abnormality. In the examined patients, muscle MRI showed ear...
متن کاملLate-onset Pompe Disease with Elevated Liver Transaminases: A Case Report
Pompe disease or type II glycogen storage disease is a rare autosomal hereditary disease. The prevalence of the disease is about 1 in 40,000 to 1 in 300,000 population. It usually occurs as a result of glycogen accretion following acid maltase deficiency. The current treatment is enzyme replacement therapy, which may slow down the disease progression. Sometimes, the clinical presentation can be...
متن کاملThe clinical relevance of outcomes used in late-onset Pompe disease: can we do better?
Pompe disease/glycogen storage disease type II, is a rare, lysosomal storage disorder associated with progressive proximal myopathy, causing a gradual loss of muscular function and respiratory insufficiency. Studies of patients with late-onset Pompe disease have used endpoints such as the 6-minute walking test (6MWT) and forced vital capacity (FVC) to assess muscular and respiratory function du...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 30 شماره
صفحات -
تاریخ انتشار 2011